EP Patent

EP1881001A1 — HCV NS-3 serine protease inhibitors

Assigned to Janssen R&D Ireland ULC · Expires 2008-01-23 · 18y expired

What this patent protects

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

USPTO Abstract

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

Drugs covered by this patent

Patent Metadata

Patent number: EP1881001A1
Jurisdiction: EP
Classification: —
Expires: 2008-01-23
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.